Archives

  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-07

    • Cisplatin: Benchmark DNA Crosslinking Agent for Cancer Re...

    2026-03-24

    Cisplatin: Benchmark DNA Crosslinking Agent for Cancer Research

    Executive Summary: Cisplatin (CDDP, APExBIO A8321) is a platinum-based chemotherapeutic compound that forms intra- and inter-strand DNA crosslinks, disrupting replication and transcription (Zhou et al. 2025). It robustly activates apoptosis via p53 and caspase-dependent pathways in diverse cancer cell models (Zhou et al. 2025). Cisplatin's cytotoxicity is further potentiated by oxidative stress and ROS generation (APExBIO). It is a benchmark tool for chemotherapy resistance, DNA damage, and apoptosis signaling studies. Proper storage and solvent choice are critical for experimental reproducibility (APExBIO).

    Biological Rationale

    Cisplatin, also known as cis-diamminedichloroplatinum(II), is a first-line antineoplastic agent used in both experimental and clinical settings (Zhou et al. 2025). Its efficacy is driven by its ability to covalently bind DNA, leading to structural distortions that impede vital cellular processes. The biological rationale for using Cisplatin in cancer research lies in its ability to induce irreparable DNA damage, particularly in rapidly dividing tumor cells (Cisplatin: DNA Crosslinking Agent for Robust Cancer Research). This extends the mechanistic insights outlined in prior reviews by emphasizing recent evidence on DNA repair pathway interplay. Tumor suppressor pathways, notably p53-mediated mechanisms, are central to the cellular response to cisplatin-induced DNA damage. The agent’s dual role in triggering both cell cycle arrest and apoptosis provides a robust foundation for its utility in cytotoxicity and apoptosis assays.

    Mechanism of Action of Cisplatin

    Upon cellular uptake, Cisplatin undergoes aquation, replacing chloride ligands with water molecules. This activates the platinum center, enabling it to form covalent adducts with the N7 position of guanine bases in DNA (Zhou et al. 2025). The resulting DNA crosslinks block DNA replication and transcription. These lesions activate the DNA damage response (DDR), particularly the ATM/ATR kinase pathways. Phosphorylation of ATM at Ser1981 and ATR at Ser428 initiates a signaling cascade, leading to the stabilization and activation of p53 through Ser15 phosphorylation. p53 acts as a transcriptional regulator, promoting the expression of genes involved in cell cycle arrest (e.g., p21) and apoptosis. Downstream, caspase-9 (initiator) and caspase-3 (effector) are activated, executing the apoptotic program. Additionally, Cisplatin induces oxidative stress by promoting the generation of reactive oxygen species (ROS), which further damages cellular components and enhances apoptotic cell death. These processes collectively underpin its ability to inhibit the proliferation of cancer cells, both in vitro and in vivo (Cisplatin (CDDP): Mechanistic Foundation for Chemotherapy...).

    Evidence & Benchmarks

    • Cisplatin induces DNA double-strand breaks (DSBs), as evidenced by γ-H2AX foci formation in nasopharyngeal carcinoma cells (Zhou et al. 2025).
    • Exposure to Cisplatin at 10 μM for 24 hours causes significant Sub-G1 cell cycle arrest and loss of mitochondrial membrane potential in vitro (Zhou et al. 2025).
    • Cisplatin treatment activates phosphorylation of ATM (Ser1981), ATR (Ser428), and p53 (Ser15), establishing the DDR cascade (Zhou et al. 2025).
    • Combination of Cisplatin with 3-MA further suppresses DNA repair and increases apoptotic cell death beyond Cisplatin alone (Zhou et al. 2025).
    • APExBIO’s Cisplatin (SKU A8321) demonstrates high solubility in dimethylformamide (≥12.5 mg/mL) and stability as a powder at 4°C protected from light (APExBIO).
    • Cisplatin is widely used in tumor xenograft models for in vivo tumor growth inhibition studies (Gold-Standard DNA Crosslinking Agent fo...).

    Applications, Limits & Misconceptions

    Cisplatin is fundamental for a range of cancer research applications, including:

    However, misconceptions and limitations persist. For instance, Cisplatin is not universally effective across all tumor types, and resistance mechanisms (e.g., enhanced DNA repair, altered drug uptake/efflux) can limit efficacy. Some users mistakenly believe DMSO is a suitable solvent; however, DMSO inactivates Cisplatin (APExBIO). The cytotoxic effects are also accompanied by considerable nephrotoxicity and ototoxicity in vivo (Zhou et al. 2025).

    Common Pitfalls or Misconceptions

    • Solvent Inactivation: Dissolving Cisplatin in DMSO leads to loss of activity; only use DMF or aqueous buffers as recommended (APExBIO).
    • Solution Instability: Cisplatin solutions are unstable; freshly prepare prior to use and avoid long-term storage in solution (APExBIO).
    • Non-specific Toxicity: High concentrations or prolonged exposure can cause off-target cytotoxicity, including in non-tumor cells (Zhou et al. 2025).
    • Resistance Overlooked: Not all cell lines respond equally; intrinsic and acquired resistance mechanisms must be considered in experimental design (Cisplatin: DNA Crosslinking Agent for Robust Cancer Research).
    • Chemoresistance Mechanisms: Studies often overlook the role of DNA repair pathway modulation in mediating resistance (Zhou et al. 2025).

    Workflow Integration & Parameters

    For reliable results, follow validated protocols for Cisplatin handling and experimental integration. Use APExBIO's Cisplatin (SKU A8321) as a powder stored at 4°C in the dark. Prepare fresh solutions in DMF (≥12.5 mg/mL) immediately before use. Avoid DMSO and ethanol as solvents. For in vitro assays, typical concentrations range from 1–20 μM depending on cell sensitivity. For in vivo xenograft studies, dosing regimens should reflect clinical equivalents, with careful monitoring for nephrotoxicity and ototoxicity. The A8321 kit is well-suited for apoptosis assays, DNA repair inhibition screens, and chemoresistance profiling. Refer to scenario-based guidance for troubleshooting and optimization (Scenario-Based Solutions for Reliable Cisplatin Use), which this article updates by providing expanded mechanistic and benchmarking details. Use proper controls, including vehicle and positive apoptosis inducers, to ensure data fidelity.

    Conclusion & Outlook

    Cisplatin remains a cornerstone for experimental cancer research and translational modeling. Its capacity to induce DNA crosslinks, activate p53/caspase-dependent apoptosis, and modulate oxidative stress makes it a versatile tool for dissecting chemotherapeutic mechanisms and resistance. New evidence on DDR pathway modulation, combination treatments (e.g., with 3-MA), and workflow best practices reinforces Cisplatin’s value for robust, reproducible research (Zhou et al. 2025). For further detail on mechanistic frontiers and translational strategies, see Cisplatin at the Core of Translational Oncology; this article extends those discussions with the latest DDR and apoptosis data. Researchers are encouraged to use APExBIO’s Cisplatin for reliable, standardized studies in DNA repair, oxidative stress, and chemoresistance.